Authors : K. Nikitha; Dr. B. Thanuja

Volume/Issue : Volume 9 - 2024, Issue 9 - September

---

Google Scholar : https://tinyurl.com/369tk952

Scribd : https://tinyurl.com/yc59cejn

DOI : https://doi.org/10.38124/ijisrt/IJISRT24SEP1565

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

---

Abstract : This review examines the role of antibiotics in cancer therapy, elucidating their mechanisms of action and clinical efficacy as adjuncts to traditional treatments. It discusses challenges such as antibiotic resistance and its impact on the gut microbiome, emphasizing the need for judicious use in cancer patients. Insights into future directions for optimizing antibiotic therapy in cancer management are also provided.

Keywords : Clinical, Treatments, Microbiome, Management and Resistance.

References :

1. Derosa L, Hellmann MD, Spaziano M, et al. (2021). Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Annals of Oncology, 32(1), 143–146. [DOI: https://doi.org/10.1016/j.annonc.2020.10.603]
2. Lehouritis P, Cummins J, Stanton M, et al. (2015). Local bacteria affect the efficacy of chemotherapeutic drugs. Scientific Reports, 5, 14554. [DOI: https://doi.org/10.1038/srep14554]
3. Paixão EM, Gozzi G, Vitiello L, et al. (2020). Role of gut microbiota on onset and progression of colorectal cancer: Historical review on microbiome alterations and therapies. Mini-Reviews in Medicinal Chemistry, 20(15), 1467–1478. [DOI: https://doi.org/10.2174/ 1389557520666200416082050]
4. Peng J, Zhang R, Zhao Y, et al. (2018). The gut microbiome in atherosclerotic cardiovascular disease. Nature Communications, 9(1), 1–12. [DOI: https://doi.org/10.1038/s41467-017-02514-3]
5. Routy B, Le Chatelier E, Derosa L, et al. (2018). Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science, 359(6371), 91–97. [DOI: https://doi.org/10.1126/ science.aan3706]
6. Simring D, Greer A, Mittleman B, et al. (2021). Antibiotic resistance trends in pediatric cancer patients. Infection Control & Hospital Epidemiology, 42(7), 869–874. [DOI: https://doi.org/10.1017/ ice.2021.73]
7. Sullivan MR, Danai LV, Lewis CA, et al. (2020). Quantification of microenvironmental metabolites in murine cancers reveals determinants of tumor nutrient availability. Elife, 9, e44235. [DOI: https://doi.org/ 10.7554/eLife.44235]
8. Taur Y, Jenq RR, Perales MA, et al. (2014). The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. Blood, 124(7), 1174–1182. [DOI: https://doi.org/10.1182/blood-2014-03-562737]
9. Xu J, Zhao J, Zhang R, et al. (2019). Antibiotics-induced gut microbiota dysbiosis promotes tumor initiation via affecting APC-Th1 development in mice. Biochemical and Biophysical Research Communications, 509(1), 178–186. [DOI: https://doi.org/10.1016/j.bbrc.2018.12.096]
10. Zhao S, Gao G, Li W, et al. (2021). Antimicrobial susceptibility of bacteria isolated from patients with cancer. Antimicrobial Resistance & Infection Control, 10(1), 1–7. [DOI: https://doi.org/10.1186/s13756-020-00878-8]